| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H29N2O4 |
| Molecular Weight | 385.4767 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 1 |
SHOW SMILES / InChI
SMILES
[H][C@]12CC3=C(C(O)=C(C=C3)C(N)=O)[C@@]5(CC[N@+]1(C)CC4CC4)CC(=O)CC[C@@]25O
InChI
InChIKey=ATCVVCBJNHXIEX-ZAHKBLQYSA-O
InChI=1S/C22H28N2O4/c1-24(12-13-2-3-13)9-8-21-11-15(25)6-7-22(21,28)17(24)10-14-4-5-16(20(23)27)19(26)18(14)21/h4-5,13,17,28H,2-3,6-12H2,1H3,(H2-,23,26,27)/p+1/t17-,21-,22-,24-/m1/s1
| Molecular Formula | C22H28N2O4 |
| Molecular Weight | 384.4687 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Methylsamidorphan (previously known as ALKS 37), an opioid receptor antagonist that was developed to treat opioid-induced bowel dysfunction. This drug participated in phase II clinical trial to evaluate the safety, tolerability, and efficacy when administered daily for 4 weeks to adults with Opioid-induced Constipation. However, the product profile did not satisfy the pre-specified criteria for advancing into phase III clinical trials. Based on this evaluation, was made the decision of discontinuation of the further methylsamidorphan study.
Approval Year
|
|
SALT/SOLVATE -> PARENT |
|
Showing 1 to 1 of 1 entries